Rock Creek Pharmaceuticals Inc

Rock Creek Pharmaceuticals — BioPharm America 2014

16 slides from Rock Creek Pharmaceuticals's conference presentation, Sep 24, 2014

  1. Slide 1: BioPharm America 2014

    Slide 1: BioPharm America 2014

    BioPharm America 2014 September 24, 2014

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements that will be made during this presentation constitute forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believe

  3. Slide 3: Corporate Overview

    Slide 3: Corporate Overview

    Corporate Overview • Drug development company focused on the discovery, development and commercialization of new drugs to provide therapies for chronic inflammatory disease, neurological disorders and behavioral health • Advancing into human clinical development in the UK and US • Novel compound Ana

  4. Slide 4: Anatabine: Key Attributes

    Slide 4: Anatabine: Key Attributes

    Anatabine: Key Attributes • Small molecule • Exhibits anti - inflammatory pharmacological characteristics via Cholinergic Receptor Binding • Crosses blood brain barrier • Excellent bioavailability • Well tolerated as dietary supplement by several hundred thousand users 4 4

  5. Slide 5: Potential Therapeutic Indications

    Slide 5: Potential Therapeutic Indications

    Potential Therapeutic Indications • Arthritic Conditions (Osteoarthritis) • Inflammatory Bowel Disorders (Ulcerative Colitis, Crohn’s) • Auto - Immune Disorders ( Thyroiditis ) • CNS (Alzheimer’s, Multiple Sclerosis) • Dermatology (Psoriasis) 5

  6. Slide 6: Anatabine: UK and US Regulatory Strategy

    Slide 6: Anatabine: UK and US Regulatory Strategy

    Anatabine: UK and US Regulatory Strategy • Investigational New Drug Application (IND) filed with US Food and Drug Administration (FDA) – On clinical hold pending additional data – Expect to complete additional pre - clinical studies by November 2014 – Anticipate filing response in December 2014 • Cl

  7. Slide 7: Inflammatory Signals and Signaling Pathways

    Slide 7: Inflammatory Signals and Signaling Pathways

    Inflammatory Molecules: TNF - α, IL - 1, IL - 6, IFN - γ, Cox - 2, Amyloid, etc. Inflammatory Signals 7 NF - kb Signaling pathways:

  8. Slide 8: Pre-Clinical Analysis: Experimental Autoimmune Encephalomyelitis (EAE)

    Slide 8: Pre-Clinical Analysis: Experimental Autoimmune Encephalomyelitis (EAE)

    Pre - Clinical Analysis: Experimental Autoimmune Encephalomyelitis (EAE) • Mice injected at 0 hr and 48 hrs with 300µg of Pertussis toxin • Day 1, 10 Week - old C57Bl6/J Female mice immunized with 300 µg of murine MOG35 - 55 (myelin oligodendrocyte glycoprotein) • Mice randomized in placebo group (n

  9. Slide 9: Second EAE Video

    Slide 9: Second EAE Video

    45 Second EAE Video 9 9

  10. Slide 10: Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice

    Slide 10: Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice

    10 10 Days after MOG vaccination Incidence of hind limb paralysis in Placebo or Anatabine treated EAE mice Incidence of hind limb paralysis Placebo (n=15) Anatabine (n=15)

  11. Slide 11: Anatabine: Preclinical Analysis

    Slide 11: Anatabine: Preclinical Analysis

    - Reduced nerve damage in Anatabine treated EAE mouse spinal cord 11 Anatabine : Preclinical Analysis

  12. Slide 12: Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine

    Slide 12: Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine

    Normalization of Inflammatory Spleen Cytokines in EAE mice by Anatabine 12 EAE Anatabine EAE Placebo Control

  13. Slide 13: Auto-Immune Thyroiditis: Human Trial

    Slide 13: Auto-Immune Thyroiditis: Human Trial

    • Evaluating Anatabine in Human Thyroid Health • Primary Outcome: Safety and Tolerability • Secondary Outcome: Anti - thyroid auto - antibodies, thyroid structure, and thyroid function • Enrollment 165 people: 5 - visits, 12 - week, double - blind, randomized, placebo - controlled, parallel - group

  14. Slide 14: Reduced Anti-thyroglobulin antibodies in Anatabine treated Thyroiditis patients

    Slide 14: Reduced Anti-thyroglobulin antibodies in Anatabine treated Thyroiditis patients

    14 14 Reduced Anti - thyroglobulin antibodies in Anatabine treated Thyroiditis patients Lowell R. Schmeltz et al, (2014) Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lympho cyt ic Autoimmune (Hashimoto’s) Thyroiditis: A Randomized Controlled Clinical Trial. J

  15. Slide 15: Upcoming Milestones

    Slide 15: Upcoming Milestones

    15 Upcoming Milestones 4Q14 1Q15 2Q15 Additional pre - clinical studies European CTA Filing & approval US IND Response Filed Subject dosing under CTA Safety, PK, PD data Drug Formulation development Phase IIA Efficacy studies

  16. Slide 16: Summary

    Slide 16: Summary

    Summary • Drug development company focused on the discovery, development and commercialization of new drugs to provide therapies for chronic inflammatory disease, neurological disorders and behavioral health • Advancing into human clinical development in the UK and US • Novel compound Anatabine Citr

Source: SEC EDGAR · 8-K filed Sep 24, 2014

More decks from Rock Creek Pharmaceuticals Inc